Hou Wen-Li, Chang Ming, Liu Xiao-Feng, Hu Lin-Sen, Hua Shu-Cheng
Department of Cadre Ward, The First Hospital of Jilin University, Changchun 130021, China.
Translational Medicine Research Institute, The First Hospital of Jilin University, Changchun 130021, China.
Transl Cancer Res. 2020 Feb;9(2):565-576. doi: 10.21037/tcr.2019.12.04.
Currently, the identification of Clara cell and type II alveolar epithelial cell-type cancer cells requires electron microscopy, which is a time-consuming and expensive process involving a complicated tissue sampling procedure. The aim of this study was to identify unique biomarkers for Clara cell and type II alveolar epithelial cell-type lung cancer cells, respectively, with proteomic profiling.
Six human lung adenocarcinoma cell lines (A549, NCI-H358, NCI-H1650, HCC827, NCI-H1395, and NCI-H1975) were investigated for their ultrastructural characteristics. The differentially expressed proteins (DEPs) were screened between NCI-H358 cells (Clara cell type) and A549 cells (type II alveolar epithelial cell type) using two-dimensional difference gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS/MS), and then they were validated by western blot. The protein expression levels of endoplasmic reticulum oxidoreductin 1-α (ERO1L), Clara cell 10-kD protein (CC10), and surfactant protein C (SP-C) were also determined in the six cell lines assayed.
NCI-H358 cells featured Clara cell differentiation; A549, NCI-H1975, and HCC827 cells had characteristics of type II alveolar epithelial cells; and NCI-H1395 and NCI-H1650 cells had no differentiation characteristics of any lung adenocarcinoma cell type. Five DEPs including ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1), cytokeratin 19 (CK19), cytokeratin 8 (CK8), ERO1L, and peroxiredoxin 2 (PRDX2) between NCI-H358 and A549 cells were identified for further validation; however, none of them showed suitability as an effective biomarker. Similarly, CC10 and SP-C were not appropriate biomarkers.
Cytological subtypes of NCI-H1975 and HCC827 cells were identified, but no promising biomarker was discovered in the present study.
目前,鉴定克拉拉细胞和II型肺泡上皮细胞类型的癌细胞需要电子显微镜检查,这是一个耗时且昂贵的过程,涉及复杂的组织采样程序。本研究的目的是通过蛋白质组分析分别鉴定克拉拉细胞和II型肺泡上皮细胞类型肺癌细胞的独特生物标志物。
研究了六种人肺腺癌细胞系(A549、NCI-H358、NCI-H1650、HCC827、NCI-H1395和NCI-H1975)的超微结构特征。使用二维差异凝胶电泳(2D-DIGE)和基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF-MS/MS)筛选NCI-H358细胞(克拉拉细胞类型)和A549细胞(II型肺泡上皮细胞类型)之间的差异表达蛋白(DEP),然后通过蛋白质印迹法进行验证。还测定了内质网氧化还原酶1-α(ERO1L)、克拉拉细胞10-kD蛋白(CC10)和表面活性蛋白C(SP-C)在六种检测细胞系中的蛋白表达水平。
NCI-H358细胞具有克拉拉细胞分化特征;A549、NCI-H1975和HCC827细胞具有II型肺泡上皮细胞特征;NCI-H1395和NCI-H1650细胞没有任何肺腺癌细胞类型的分化特征。鉴定出NCI-H358和A549细胞之间的五种差异表达蛋白,包括泛素羧基末端水解酶同工酶L1(UCHL1)、细胞角蛋白19(CK19)、细胞角蛋白8(CK8)、ERO1L和过氧化物酶2(PRDX2)用于进一步验证;然而,它们均未显示出作为有效生物标志物的适用性。同样,CC10和SP-C也不是合适的生物标志物。
确定了NCI-H1975和HCC827细胞的细胞学亚型,但在本研究中未发现有前景的生物标志物。